Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2022 Jan:102:107693.
doi: 10.1016/j.intimp.2021.107693. Epub 2021 May 28.

Comment on: Safety and efficacy of Favipiravir in moderate to severe SARS-CoV-2 pneumonia

Seyed MohammadReza Hashemian  1 , Batoul Khoundabi  2 , Ali Akbar Velayati  3
Affiliations
Comment

Comment on: Safety and efficacy of Favipiravir in moderate to severe SARS-CoV-2 pneumonia

Seyed MohammadReza Hashemian et al. Int Immunopharmacol. 2022 Jan.
No abstract available

PubMed Disclaimer

Comment on

  • Safety and efficacy of Favipiravir in moderate to severe SARS-CoV-2 pneumonia.
    Solaymani-Dodaran M, Ghanei M, Bagheri M, Qazvini A, Vahedi E, Hassan Saadat S, Amin Setarehdan S, Ansarifar A, Biganeh H, Mohazzab A, Khalili D, Hosein Ghazale A, Reza Heidari M, Taheri A, Khoramdad M, Mahdi Asadi M, Nazemieh M, Varshochi M, Abbasian S, Bakhtiari A, Mosaed R, Hosseini-Shokouh SJ, Shahrokhi M, Yassin Z, Ali Zohal M, Qaraati M, Rastgoo N, Sami R, Javad Eslami M, Asghari A, Namazi M, Ziaie S, Jafari-Moghaddam R, Kalantari S, Memarian M, Khodadadi J, Hossein Afshari M, Momen-Heravi M, Behzadseresht N, Reza Mobayen A, Mozafari A, Movasaghi F, Haddadzadeh Shoushtari M, Moazen J. Solaymani-Dodaran M, et al. Int Immunopharmacol. 2021 Jun;95:107522. doi: 10.1016/j.intimp.2021.107522. Epub 2021 Mar 11. Int Immunopharmacol. 2021. PMID: 33735712 Free PMC article. Clinical Trial.

Similar articles

See all similar articles

References

    1. Solaymani M., Ghanei M., Bagheri M., Qazvini A., et al. Safety and efficacy of Favipiravir in moderate to severe SARS-CoV-2 pneumonia. Int. immunopharmacol. 2021;95 - PMC - PubMed
    1. Venkatasubbaiah M., Dwarakanadha Reddy P., Satyanarayana S.V. Literature-based review of the drugs used for the treatment of COVID-19. Curr. Med. Res. Pract. 2020;10(3):100–109. - PMC - PubMed
    1. Şimşek Yavuz S., Ünal S. Antiviral treatment of COVID-19. Turk. J. Med. Sci. 2020;50(SI- 1):611–619. - PMC - PubMed
    1. Shannon A., Selisko B., Le N., et al. Favipiravir strikes the SARS-CoV-2 at its Achilles heel, the RNA polymerase. bioRxiv. 2020 2020.05.15.098731.
    1. Du Y.X., Chen X.P. Favipiravir: Pharmacokinetics and concerns about clinical trials for 2019-nCoV infection. Clin. Pharmacol. Ther. 2020;108(2) - PubMed